Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Sep 2025 value amounting to -$207.0 million.

  • Madrigal Pharmaceuticals' Cash from Investing Activities fell 2.28% to -$207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 92.66%. This contributed to the annual value of -$274.4 million for FY2024, which is 45.40% up from last year.
  • Madrigal Pharmaceuticals' Cash from Investing Activities amounted to -$207.0 million in Q3 2025, which was down 532.52% from $47.9 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $163.9 million during Q1 2025, with a 5-year trough of -$362.1 million in Q4 2023.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$48.0 million (2024), whereas its average is -$70.2 million.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Cash from Investing Activities soared by 426.03% in 2021, and later crashed by 3,171.65% in 2024.
  • Quarterly analysis of 5 years shows Madrigal Pharmaceuticals' Cash from Investing Activities stood at $15.6 million in 2021, then soared by 324.39% to $66.4 million in 2022, then tumbled by 645.47% to -$362.1 million in 2023, then skyrocketed by 86.76% to -$48.0 million in 2024, then decreased by 2.28% to -$207.0 million in 2025.
  • Its last three reported values are -$207.0 million in Q3 2025, $47.9 million for Q2 2025, and $163.9 million during Q1 2025.